A new study published in the Journal of the National Cancer Institute indicates that the customary pembrolizumab dose for treatment of metastatic non-small cell lung cancer may be higher than is needed for effective treatment. In October 2016 ...
Roche Plunges After a Key Breast Cancer Treatment Trial Disappoints
Roche AG (RHHBY) shares fell the most in more than two years Tuesday after data that indicated a new form of breast cancer treatment by the Swiss drugmaker, which combined an older drug with a recently developed one, had only a limited impact on ...
No comments:
Post a Comment